CY1112193T1 - Σταθεροποιημενα υγρα σκευασματα ιντερφερονης - Google Patents

Σταθεροποιημενα υγρα σκευασματα ιντερφερονης

Info

Publication number
CY1112193T1
CY1112193T1 CY20111101217T CY111101217T CY1112193T1 CY 1112193 T1 CY1112193 T1 CY 1112193T1 CY 20111101217 T CY20111101217 T CY 20111101217T CY 111101217 T CY111101217 T CY 111101217T CY 1112193 T1 CY1112193 T1 CY 1112193T1
Authority
CY
Cyprus
Prior art keywords
interferon
stabilized liquid
cyclodextrin
room temperature
formulations
Prior art date
Application number
CY20111101217T
Other languages
English (en)
Inventor
Curto Maria Dorly Del
Original Assignee
Ares Trading S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S.A. filed Critical Ares Trading S.A.
Publication of CY1112193T1 publication Critical patent/CY1112193T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Στην παρούσα περιγράφεται σταθεροποιημένη υγρή φαρμακευτική σύνθεση η οποία περιέχει μια ιντερφερόνη (IFN) ή μια ισόμορφη, μουτεΐνη, συντηγμένη πρωτεΐνη, λειτουργικό παράγωγο, ενεργό θραύσμα ή άλας αυτής, όπου το εν λόγω σκεύασμα είναι ένα διάλυμα το οποίο περιλαμβάνει ένα ρυθμιστικό διάλυμα, μια κυκλοδεξτρίνη, έναν παράγοντα ισοτονικότητας και ένα αντιοξειδωτικό. Κατά προτίμηση, η ιντερφερόνη είναι η ιντερφερόνη-β-1α και η κυκλοδεξτρίνη είναι η HPBCD. Αυτά τα σκευάσματα είναι ευσταθή σε θερμοκρασία δωματίου, επιφέροντας έτσι το πλεονέκτημα του χαμηλότερου κόστους για την αποθήκευση του σκευάσματος και της αυξημένης ασφάλειας για τον ασθενή σε ότι αφορά σε πιθανά «λάθη» κατά το χειρισμό. Είναι γεγονός ότι εάν αυτά τα σκευάσματα είναι ευσταθή σε θερμοκρασία δωματίου μειώνεται ο κίνδυνος σχηματισμού προϊόντος αποικοδόμησης που δυνητικά ευθύνονται για δυσμενείς παρενέργειες (π.χ. ανοσογονικότητα).
CY20111101217T 2003-12-11 2011-12-06 Σταθεροποιημενα υγρα σκευασματα ιντερφερονης CY1112193T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03104646 2003-12-11
EP04103349 2004-07-13
EP04820468A EP1691825B1 (en) 2003-12-11 2004-12-10 Stabilized interferon liquid formulations

Publications (1)

Publication Number Publication Date
CY1112193T1 true CY1112193T1 (el) 2015-12-09

Family

ID=34702349

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101217T CY1112193T1 (el) 2003-12-11 2011-12-06 Σταθεροποιημενα υγρα σκευασματα ιντερφερονης

Country Status (18)

Country Link
US (1) US7846427B2 (el)
EP (1) EP1691825B1 (el)
JP (1) JP4658961B2 (el)
AT (1) ATE526032T1 (el)
AU (1) AU2004298781B2 (el)
BR (1) BRPI0416980A (el)
CA (1) CA2547822A1 (el)
CY (1) CY1112193T1 (el)
DK (1) DK1691825T3 (el)
ES (1) ES2374530T3 (el)
HR (1) HRP20110699T1 (el)
IL (1) IL176021A0 (el)
NO (1) NO20063108L (el)
PL (1) PL1691825T3 (el)
PT (1) PT1691825E (el)
RS (1) RS52218B (el)
SI (1) SI1691825T1 (el)
WO (1) WO2005058346A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
KR20070012464A (ko) * 2004-05-17 2007-01-25 아레스 트레이딩 에스.아. 하이드로겔 인터페론 제제
NZ580686A (en) 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
EA201070773A1 (ru) * 2007-12-20 2010-12-30 Мерк Сероно С. А. Составы пэг-интерферона-бета
US20100203014A1 (en) * 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
US20150283252A1 (en) * 2012-10-26 2015-10-08 Lupin Limited Stable pharmaceutical composition of peginterferon alpha-2b
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
MX2020007270A (es) * 2017-09-27 2020-08-17 Novartis Ag Formulacion parenteral que comprende siponimod.
CN111494611A (zh) * 2020-06-08 2020-08-07 长春生物制品研究所有限责任公司 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液
CN113797317B (zh) * 2021-10-26 2024-01-09 科兴生物制药股份有限公司 一种组合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
ZA9610374B (en) * 1995-12-11 1997-06-23 Elan Med Tech Cartridge-based drug delivery device
JP2001526033A (ja) * 1997-12-08 2001-12-18 ジェネンテク・インコーポレイテッド ヒトインターフェロン−イプシロンというｉ型インターフェロン
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2003002152A2 (en) * 2001-06-29 2003-01-09 Maxygen Aps Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
KR20070012464A (ko) 2004-05-17 2007-01-25 아레스 트레이딩 에스.아. 하이드로겔 인터페론 제제
CN1993139B (zh) 2004-06-01 2011-02-16 阿雷斯贸易股份有限公司 稳定的干扰素液体制剂

Also Published As

Publication number Publication date
SI1691825T1 (sl) 2011-12-30
PT1691825E (pt) 2011-10-12
PL1691825T3 (pl) 2012-02-29
DK1691825T3 (da) 2011-12-05
IL176021A0 (en) 2006-10-05
US20070104682A1 (en) 2007-05-10
US7846427B2 (en) 2010-12-07
AU2004298781B2 (en) 2010-04-01
JP4658961B2 (ja) 2011-03-23
HRP20110699T1 (hr) 2011-10-31
RS52218B (en) 2012-10-31
EP1691825A1 (en) 2006-08-23
CA2547822A1 (en) 2005-06-30
BRPI0416980A (pt) 2007-02-21
AU2004298781A1 (en) 2005-06-30
NO20063108L (no) 2006-07-04
ATE526032T1 (de) 2011-10-15
JP2007513925A (ja) 2007-05-31
EP1691825B1 (en) 2011-09-28
WO2005058346A1 (en) 2005-06-30
ES2374530T3 (es) 2012-02-17

Similar Documents

Publication Publication Date Title
CY1112193T1 (el) Σταθεροποιημενα υγρα σκευασματα ιντερφερονης
ES2418833T3 (es) Formulaciones líquidas de interferón estabilizadas
DE502004012418D1 (de) Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa)
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
CY1115233T1 (el) Υγρα σταθεροποιημενα σκευασματα ιντερφερονης-βητα σε επικαλυμμενους περιεκτες φαρμακευτικης χρησης
NO953278L (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
DE69418468D1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
CA2304808A1 (en) Liquid interferon-.beta. formulations
PL335571A1 (en) Stabilisation of acid-sensitive benzimidazoles by combining them with amino acids and cyclodextrins
DK0458894T3 (da) Lipidexcipiens til nasal afgivelse og topisk påføring
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
BRPI0410488A (pt) composição farmacêutica lìquida estabilizada livre de hsa, método para preparação de composição farmacêutica lìquida estabilizada livre de hsa, recipiente vedado hermeticamente e kit para administração de múltiplas doses de composição farmacêutica lìquida estabilizada livre de hsa'
ATE275974T1 (de) Zusammensetzungen enthaltend glykolderivate, alkohole und vitamin d
HUP0302311A2 (hu) Gyógyászati aeroszol-készítmények
JP4871720B2 (ja) 血清アルブミンを含まない、安定なヒトエリスロポエチン水溶液
AU2014351326B2 (en) Formulation for gonadotropins
JP3714951B2 (ja) Ｉｌ−６含有薬剤組成物
JP2010120966A (ja) 安定化されたタンパク組成物
CO4830457A1 (es) Preparados efervescentes
JP2008050320A (ja) インターフェロン−β含有医薬組成物
DE60134883D1 (de) Interferon- und interleukin-derivate mit langzeitwirkung und diese enthaltende pharmazeutische zusammensetzungen
DE69902925D1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen
BR0215498A (pt) Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes